Related Experiment Video

Updated: Jul 26, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

The management of patients with mild hepatitis C

C Verslype1, P Michielsen, M Adler

  • 1Department of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium. Chris.Verslype@uz.kuleuven.ac.be

Acta Gastro-Enterologica Belgica
|November 5, 2005
PubMed

Insights

Hepatitis C virus (HCV) infection causes chronic liver disease. Identifying mild cases that progress is challenging, but treatment is safe and effective for these patients.

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis C virus (HCV) infection is a significant global health concern, leading to chronic hepatitis, cirrhosis, and liver cancer.
  • Chronic hepatitis C presents as a heterogeneous disease, making it difficult to predict which patients with mild initial symptoms will develop advanced liver conditions.

Purpose of the Study:

  • To discuss the challenges in identifying progressive liver disease in mild hepatitis C cases.
  • To emphasize the safety and efficacy of pegylated interferon and ribavirin treatment in patients with mild hepatitis C.
  • To highlight the importance of individualized treatment decisions for chronic hepatitis C.

Main Methods:

  • Review of histological criteria for disease severity assessment.
  • Evaluation of co-factors such as age, alcohol consumption, and steatosis.
  • Consideration of persistently normal serum transaminases over 18 months as an indicator of a benign course.

Main Results:

  • Identifying patients with mild hepatitis C who will progress to advanced liver disease remains difficult.
  • Serum transaminases persistently normal for 18 months may suggest a more favorable disease trajectory.
  • Treatment with pegylated interferon and ribavirin is a safe and effective option for patients with mild hepatitis C.

Conclusions:

  • Individualized treatment decisions for chronic hepatitis C are crucial.
  • Treatment initiation should consider liver biopsy findings, potential side effects, response probability, and patient motivation.
  • Mild hepatitis C patients should not be excluded from treatment consideration due to disease presentation alone.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...